FI973002L - Terapeuttinen yhdiste - rasvahappokonjugaatit - Google Patents
Terapeuttinen yhdiste - rasvahappokonjugaatit Download PDFInfo
- Publication number
- FI973002L FI973002L FI973002A FI973002A FI973002L FI 973002 L FI973002 L FI 973002L FI 973002 A FI973002 A FI 973002A FI 973002 A FI973002 A FI 973002A FI 973002 L FI973002 L FI 973002L
- Authority
- FI
- Finland
- Prior art keywords
- fatty acid
- therapeutic compound
- acid conjugates
- conjugates
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN0583A AUPN058395A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 5 |
| AUPN0584A AUPN058495A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 6 |
| AUPN0582A AUPN058295A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 4 |
| AUPN0581A AUPN058195A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 3 |
| AUPN0585A AUPN058595A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 7 |
| AUPN0580A AUPN058095A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 2 |
| AUPN0586A AUPN058695A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 8 |
| PCT/AU1996/000015 WO1996022303A1 (en) | 1995-01-16 | 1996-01-15 | Therapeutic compound - fatty acid conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI973002A0 FI973002A0 (fi) | 1997-07-15 |
| FI973002L true FI973002L (fi) | 1997-08-19 |
| FI973002A7 FI973002A7 (fi) | 1997-08-19 |
Family
ID=27560724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973002A FI973002A7 (fi) | 1995-01-16 | 1996-01-15 | Terapeuttinen yhdiste - rasvahappokonjugaatit |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US5952499A (fi) |
| EP (1) | EP0804459A4 (fi) |
| JP (1) | JPH11502509A (fi) |
| BR (1) | BR9607492A (fi) |
| CA (1) | CA2210500A1 (fi) |
| FI (1) | FI973002A7 (fi) |
| NO (1) | NO973283L (fi) |
| NZ (1) | NZ298712A (fi) |
| RU (1) | RU2166512C2 (fi) |
| WO (1) | WO1996022303A1 (fi) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| DE19631189A1 (de) * | 1996-08-02 | 1998-02-05 | Max Delbrueck Centrum | Neuartige kationische Amphiphile für den liposomalen Gentransfer |
| US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| JP2002523071A (ja) * | 1998-08-31 | 2002-07-30 | バイオジェン インコーポレイテッド | 記憶エフェクターt細胞を調整する方法と組成物 |
| AUPP751398A0 (en) * | 1998-12-04 | 1999-01-07 | Commonwealth Scientific And Industrial Research Organisation | Methotrexate derivatives |
| US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
| CA2369595C (en) | 1999-04-23 | 2010-10-05 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
| US6765019B1 (en) | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| CN1191861C (zh) * | 1999-05-24 | 2005-03-09 | 三共株式会社 | 含有抗Fas抗体的药物组合物 |
| GB9930026D0 (en) * | 1999-12-21 | 2000-02-09 | Univ Sheffield | Novel compounds of unsaturated fatty acids |
| US6485740B1 (en) * | 2000-03-14 | 2002-11-26 | Yutoku Pharmaceutical Ind., Co., Ltd. | Transdermal methotrexate preparations |
| WO2005032474A2 (en) * | 2003-09-30 | 2005-04-14 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| EP1423107B1 (en) * | 2001-03-23 | 2012-05-09 | Luitpold Pharmaceuticals, Inc. | Fatty alcohol drug conjugates |
| EP1427407A4 (en) * | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | FAT AMIN DRUG CONJUGATES |
| IL158882A0 (en) * | 2001-06-05 | 2004-05-12 | Control Delivery Sys Inc | Sustained-release analgesic compounds |
| CA2454618C (en) * | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
| US7045543B2 (en) | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070172478A1 (en) * | 2004-02-06 | 2007-07-26 | Astellas Us Llc | Methods of treating skin disorders |
| MXPA06012744A (es) * | 2004-05-04 | 2007-02-19 | Genaissance Pharmaceutical Inc | Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento. |
| US7662921B2 (en) * | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| CA2592320C (en) | 2004-12-22 | 2015-11-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7724373B2 (en) * | 2005-12-16 | 2010-05-25 | Indiana University Research & Technology Corporation | Sub-micron surface plasmon resonance sensor systems |
| DE102006035083A1 (de) * | 2006-07-28 | 2008-01-31 | medac Gesellschaft für klinische Spezialgeräte mbH | Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel |
| KR101443573B1 (ko) | 2006-10-12 | 2014-11-03 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| WO2009121018A2 (en) * | 2008-03-27 | 2009-10-01 | University Of Kentucky Research Foundation | Opioid-nornicotine codrugs for pain management |
| US8710070B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| WO2010035261A2 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
| MX2011004095A (es) * | 2008-10-17 | 2011-07-28 | Pharmacofore Inc | Composiciones farmaceuticas con liberacion atenuada de opioides fenolicos. |
| US8603999B2 (en) | 2008-12-05 | 2013-12-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
| US20100240883A1 (en) * | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
| DK2531221T3 (da) | 2010-02-03 | 2019-06-17 | Nanopet Pharma Gmbh | Polyanioniske multivalente makromolekyler til intracellulær målretning af proliferation og proteinsyntese |
| WO2013063204A1 (en) | 2011-10-26 | 2013-05-02 | Kempharm, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
| EP3226907A1 (en) | 2014-12-02 | 2017-10-11 | Kempharm, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof |
| WO2017106957A1 (en) * | 2015-12-23 | 2017-06-29 | The University Of British Columbia | Lipid-linked prodrugs |
| US20230137562A1 (en) | 2017-06-07 | 2023-05-04 | Adrx, Inc. | Tau aggregation inhibitors |
| AU2018318319A1 (en) | 2017-08-18 | 2020-02-20 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| RU2713838C1 (ru) * | 2019-04-23 | 2020-02-07 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ анестезиологического обеспечения при селективной доставке химиопрепарата к сетчатке глаза при лечении интраокулярной ретинобластомы у детей |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4939174A (en) * | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| DE3904119A1 (de) * | 1989-02-11 | 1990-08-16 | Hoechst Ag | Polymerfixiertes methotrexat, verfahren zur herstellung und verwendung |
| EP0506748B1 (en) * | 1989-12-22 | 1995-12-13 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
| US5583198A (en) * | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
| JPH0421694A (ja) * | 1990-05-16 | 1992-01-24 | Asahi Chem Ind Co Ltd | 新規なヌクレオシド―リン脂質複合体 |
| EP0576605A4 (en) * | 1991-03-19 | 1994-06-08 | Vithal J Rajadhyaksha | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
| DE69230855D1 (de) * | 1991-07-26 | 2000-05-04 | Commw Scient Ind Res Org | System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung |
| DE4310516A1 (de) * | 1993-02-09 | 1994-08-11 | Boehringer Mannheim Gmbh | Lipoprotein (a)-Peptide und deren Verwendung |
| DE4311987A1 (de) * | 1993-04-07 | 1994-10-13 | Schering Ag | Neue Glucocorticoide |
| NZ269773A (en) * | 1993-08-02 | 1997-11-24 | Commw Scient Ind Res Org | Therapeutic compound conjugates; such conjugates comprise a compound bound to one to three acyl groups derived from fatty acids |
-
1996
- 1996-01-15 CA CA002210500A patent/CA2210500A1/en not_active Abandoned
- 1996-01-15 EP EP96900469A patent/EP0804459A4/en not_active Withdrawn
- 1996-01-15 JP JP8521914A patent/JPH11502509A/ja not_active Ceased
- 1996-01-15 BR BR9607492A patent/BR9607492A/pt not_active IP Right Cessation
- 1996-01-15 US US08/875,098 patent/US5952499A/en not_active Expired - Fee Related
- 1996-01-15 NZ NZ298712A patent/NZ298712A/xx unknown
- 1996-01-15 FI FI973002A patent/FI973002A7/fi unknown
- 1996-01-15 WO PCT/AU1996/000015 patent/WO1996022303A1/en not_active Ceased
- 1996-01-15 RU RU97113473/04A patent/RU2166512C2/ru not_active IP Right Cessation
-
1997
- 1997-07-15 NO NO973283A patent/NO973283L/no not_active Application Discontinuation
-
1999
- 1999-04-12 US US09/289,715 patent/US6281376B1/en not_active Expired - Fee Related
-
2001
- 2001-05-24 US US09/863,385 patent/US20030023104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2210500A1 (en) | 1996-07-25 |
| EP0804459A1 (en) | 1997-11-05 |
| US6281376B1 (en) | 2001-08-28 |
| US20030023104A1 (en) | 2003-01-30 |
| BR9607492A (pt) | 1999-06-29 |
| NZ298712A (en) | 1998-12-23 |
| FI973002A0 (fi) | 1997-07-15 |
| EP0804459A4 (en) | 1999-05-26 |
| WO1996022303A1 (en) | 1996-07-25 |
| NO973283L (no) | 1997-09-08 |
| JPH11502509A (ja) | 1999-03-02 |
| FI973002A7 (fi) | 1997-08-19 |
| NO973283D0 (no) | 1997-07-15 |
| US5952499A (en) | 1999-09-14 |
| RU2166512C2 (ru) | 2001-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI973002A0 (fi) | Terapeuttinen yhdiste - rasvahappokonjugaatit | |
| ATE211131T1 (de) | Arylsulfonylaminohydroxamsäurederivate | |
| BR9602637A (pt) | Cateter | |
| BR9610153A (pt) | Formulações farmacêuticas | |
| BR9611626A (pt) | Formulações farmacéuticas | |
| DE69627539D1 (de) | Verpackungsfreie bioelektrode | |
| DE69630305D1 (de) | Elektrodenkatheter | |
| FI971279L (fi) | Lääkkeitä | |
| BR9602635A (pt) | Conjunto de cateter | |
| NO963625D0 (no) | Kateter | |
| DK0822982T3 (da) | Cyclomaltodextringlucanotransferasevarianter | |
| DE69606550D1 (de) | Medizinischen verbindungsanordnung | |
| DE69517172D1 (de) | Therapeutische verbindungen | |
| DE69606053D1 (de) | Modifizierte fluorsulfonsäure | |
| BR9600809A (pt) | Medicamento | |
| NO972868D0 (no) | Oligonukleotid-dendrimer konjugater | |
| ITMI941169A0 (it) | Formulazioni farmaceutiche | |
| EP0837863A4 (en) | DISODIUM ALENDRONATE PREPARATIONS | |
| FI970195L (fi) | Trifluormetyylikinoliinikarboksyylihappojohdannainen | |
| KR960026722U (ko) | 견인치료기 | |
| DK0818964T3 (da) | Doseringsstift | |
| DE69616554D1 (de) | Sialinsäure-derivate | |
| DE59610423D1 (de) | Partikulare arzneiform | |
| FI973755A7 (fi) | Viistokantaniitti | |
| KR970005245A (ko) | 교합기 |